Fractyl Trial Targets Post-GLP-1 Weight Maintenance
Fractyl Health has completed randomization in REMAIN-1, its sham-controlled pivotal cohort evaluating the Revita endoscopic procedure for weight maintenance...
First Patient Dosed in MindRank’s AI-Designed GLP-1 Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of its oral...
Ophirex Supplies Marimastat for Snakebite Treatment Study
Phase 2 platform funding of £4.2 million is backing TOCSINS, a multicountry trial evaluating oral snakebite therapies, with Ophirex...
MindRank’s Breakthrough AI GLP-1 Drug Enters Phase III Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of MDR-001, an...
New Hope: Stem Cell Trial Improves Age-Related Frailty
In a Phase 2b randomized, dose-finding study of 148 ambulatory adults with aging-related frailty, intravenous laromestrocel improved six-minute walk...
ITM Reveals New pNETs Analysis from COMPETE Trial at ENETS
Phase 3 COMPETE met its primary endpoint, with 177Lu-edotreotide delivering a clinically and statistically significant improvement in progression-free survival...
Tempest Reveals Emerging Data From TPST-2003 Redeem-1 Study
TPST-2003 delivered a 100% complete response rate among the six efficacy-evaluable patients in the ongoing REDEEM-1 Phase 1/2a trial,...
Crescent BioPharma Doses First Patient in CR-001 Tumor Trial
Crescent Biopharma has dosed the first patient in ASCEND (NCT07335497), a global, open-label Phase 1/2 trial of CR-001, a...
Starton Doses First Patient in Phase 2a Myeloma Study
In a small Phase 1b study of six relapsed/refractory multiple myeloma patients, continuous low‑dose lenalidomide (STAR-LLD) produced one complete...
Klothea Bio Launches mRNA Trial for Lifespan Extension
Klothea Bio has initiated a randomized, double-blind, placebo-controlled Phase 1b study of AKL003, an intravenous alpha Klotho mRNA therapeutic...